Literature DB >> 29476738

Identification of a non-competitive inhibitor of Plasmodium falciparum aspartate transcarbamoylase.

Sergey Lunev1, Soraya S Bosch2, Fernando A Batista1, Chao Wang1, Jingyao Li1, Marleen Linzke2, Paul Kruithof1, George Chamoun1, Alexander S S Dömling1, Carsten Wrenger3, Matthew R Groves4.   

Abstract

Aspartate transcarbamoylase catalyzes the second step of de-novo pyrimidine biosynthesis. As malarial parasites lack pyrimidine salvage machinery and rely on de-novo production for growth and proliferation, this pathway is a target for drug discovery. Previously, an apo crystal structure of aspartate transcarbamoylase from Plasmodium falciparum (PfATC) in its T-state has been reported. Here we present crystal structures of PfATC in the liganded R-state as well as in complex with the novel inhibitor, 2,3-napthalenediol, identified by high-throughput screening. Our data shows that 2,3-napthalediol binds in close proximity to the active site, implying an allosteric mechanism of inhibition. Furthermore, we report biophysical characterization of 2,3-napthalenediol. These data provide a promising starting point for structure based drug design targeting PfATC and malarial de-novo pyrimidine biosynthesis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2,3-napthalenediol; Aspartate transcarbamoylase; Inhibitor; Malaria; Pyrimidine biosynthesis

Mesh:

Substances:

Year:  2018        PMID: 29476738     DOI: 10.1016/j.bbrc.2018.02.112

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

Review 1.  Novel Highlight in Malarial Drug Discovery: Aspartate Transcarbamoylase.

Authors:  Chao Wang; Arne Krüger; Xiaochen Du; Carsten Wrenger; Matthew R Groves
Journal:  Front Cell Infect Microbiol       Date:  2022-03-04       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.